Published in Oncol Lett on July 26, 2017
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol (2003) 14.41
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75
WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res (2000) 4.07
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 2.98
WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A (2001) 2.79
Chromosome translocations in multiple myeloma. Oncogene (2001) 2.61
Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet (2000) 2.56
Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci U S A (2007) 2.37
WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res (2001) 2.12
Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene (2005) 1.90
Common fragile sites: mechanisms of instability revisited. Trends Genet (2011) 1.80
Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res (2002) 1.62
Common fragile sites. Cancer Lett (2005) 1.48
5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res (2001) 1.46
WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res (2003) 1.42
A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res (2000) 1.39
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol (2014) 1.39
Common chromosomal fragile sites and cancer: focus on FRA16D. Cancer Lett (2005) 1.36
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood (2013) 1.35
Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood (1997) 1.35
The molecular basis of fragile sites in human chromosomes. Curr Opin Genet Dev (1995) 1.32
Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res (2003) 1.32
Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene (2002) 1.31
The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics (2000) 1.31
WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res (2003) 1.28
Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res (1998) 1.28
A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer (2009) 1.19
Generation and characterization of mice carrying a conditional allele of the Wwox tumor suppressor gene. PLoS One (2009) 1.18
The tumor suppressor gene WWOX links the canonical and noncanonical NF-κB pathways in HTLV-I Tax-mediated tumorigenesis. Blood (2010) 1.16
Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity. Int J Cancer (2007) 1.15
Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor suppressor protein. Oncogene (2009) 1.15
WWOX hypomorphic mice display a higher incidence of B-cell lymphomas and develop testicular atrophy. Genes Chromosomes Cancer (2007) 1.13
DNA instability at chromosomal fragile sites in cancer. Curr Genomics (2010) 1.11
Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes Cancer (2001) 1.10
Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol (2013) 1.07
p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood (2001) 1.06
Identification and fine mapping of a region showing a high frequency of allelic imbalance on chromosome 16q23.2 that corresponds to a prostate cancer susceptibility locus. Cancer Res (2000) 1.06
Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res (2007) 1.05
Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol (2013) 1.04
WWOX, the common fragile site FRA16D gene product, regulates ATM activation and the DNA damage response. Proc Natl Acad Sci U S A (2014) 1.03
WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int J Oncol (2005) 0.99
Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res (1998) 0.97
Very large common fragile site genes and their potential role in cancer development. Cell Mol Life Sci (2014) 0.96
Updating the mechanisms of common fragile site instability: how to reconcile the different views? Cell Mol Life Sci (2014) 0.90
De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia (2000) 0.89
Methylation status of WWOX gene promoter CpG islands in epithelial ovarian cancer and its clinical significance. Biomed Rep (2013) 0.89
Homozygous deletions may be markers of nearby heterozygous mutations: The complex deletion at FRA16D in the HCT116 colon cancer cell line removes exons of WWOX. Genes Chromosomes Cancer (2008) 0.89
Aberrant methylation in promoter-associated CpG islands of multiple genes in therapy-related leukemia. Int J Oncol (2003) 0.86
DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment. Cell Cycle (2013) 0.86
Methylation status of nine tumor suppressor genes in multiple myeloma. Int J Hematol (2010) 0.85
DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance. Ann Hematol (2010) 0.84
Association between CpG island methylation of the WWOX gene and its expression in breast cancers. Tumour Biol (2009) 0.82
Epigenetic and genetic alterations affect the WWOX gene in head and neck squamous cell carcinoma. PLoS One (2015) 0.81
Hypermethylation-mediated reduction of WWOX expression in intraductal papillary mucinous neoplasms of the pancreas. Br J Cancer (2009) 0.79
Association of downregulation of WWOX with poor prognosis in patients with intrahepatic cholangiocarcinoma after curative resection. J Gastroenterol Hepatol (2015) 0.79